首頁 > 產(chǎn)品中心 > 科研抗體 > 標記一抗
產(chǎn)品中心
相關(guān)產(chǎn)品
標記一抗
英文名稱Anti-AVPR1B/FITC
中文名稱:FITC標記的抗利尿激素受體1B抗體
別 名AVP Receptor V3; Antidiuretic hormone receptor 1b; Arginine vasopressin receptor 1B; Arginine vasopressin receptor 3; AVPR V1b; AVPR V3; Avpr1b; AVPR3; Pituitary vasopressin receptor 3; V1bR; V1BR_HUMAN; Vasopressin V1b receptor; Vasopressin V3 receptor; VPR3.
規(guī)格:100ul
說 明 書100ul
研究領(lǐng)域神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 生長因子和激素 細胞膜受體 G蛋白偶聯(lián)受體 G蛋白信號 細胞膜蛋白
抗體來源Rabbit
克隆類型Polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Horse,
產(chǎn)品應(yīng)用ICC=1:50-200 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量47kDa
細胞定位細胞膜
性 狀Lyophilized or Liquid
濃 度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human AVP Receptor V3
亞 型IgG
純化方法affinity purified by Protein A
儲 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹background:
Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2)
中文名稱:FITC標記的抗利尿激素受體1B抗體
別 名AVP Receptor V3; Antidiuretic hormone receptor 1b; Arginine vasopressin receptor 1B; Arginine vasopressin receptor 3; AVPR V1b; AVPR V3; Avpr1b; AVPR3; Pituitary vasopressin receptor 3; V1bR; V1BR_HUMAN; Vasopressin V1b receptor; Vasopressin V3 receptor; VPR3.
詳細介紹：
規(guī)格:100ul
說 明 書100ul
研究領(lǐng)域神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 生長因子和激素 細胞膜受體 G蛋白偶聯(lián)受體 G蛋白信號 細胞膜蛋白
抗體來源Rabbit
克隆類型Polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Horse,
產(chǎn)品應(yīng)用ICC=1:50-200 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量47kDa
細胞定位細胞膜
性 狀Lyophilized or Liquid
濃 度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human AVP Receptor V3
亞 型IgG
純化方法affinity purified by Protein A
儲 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
相關(guān)資料：
產(chǎn)品介紹background:
Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2)
